Illumina, Inc. (ILMN): Price and Financial Metrics


Illumina, Inc. (ILMN)

Today's Latest Price: $372.12 USD

7.27 (-1.92%)

Updated Jul 7 6:55pm

Add ILMN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ILMN Stock Summary

  • Illumina Inc's market capitalization of $55,770,330,000 is ahead of 96.73% of US-listed equities.
  • ILMN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 568.92 -- higher than 93.63% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Illumina Inc is higher than 93.31% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are NTES, VMW, ATVI, EW, and SQ.
  • Visit ILMN's SEC page to see the company's official filings. To visit the company's web site, go to www.illumina.com.
ILMN Daily Price Range
ILMN 52-Week Price Range

ILMN Stock Price Chart Technical Analysis Charts


ILMN Price/Volume Stats

Current price $372.12 52-week high $384.21
Prev. close $379.39 52-week low $196.78
Day low $369.11 Volume 719,800
Day high $378.79 Avg. volume 1,252,924
50-day MA $346.89 Dividend yield N/A
200-day MA $311.06 Market Cap 54.70B

Illumina, Inc. (ILMN) Company Bio


Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.

ILMN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$372.12$121.46-67%

We started the process of determining a valid price forecast for Illumina Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Illumina Inc ranked in the 23th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Illumina Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 23.21 -- which is good for besting 86.44% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.65% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.64% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-68%
1%-68%
2%-67%
3%-67%
4%-67%
5%-66%

BHC, MD, MTD, WST, and ABT can be thought of as valuation peers to ILMN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


ILMN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ILMN Latest Social Stream


Loading social stream, please wait...

View Full ILMN Social Stream

Latest ILMN News From Around the Web

Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.

Illumina Sets Up In Shallow Base

Illumina is nearing a 377.90 flat-base buy point. The genomics sequencing machine giant previously broke out from a deep base, either a cup or wild, long double-bottom. Very deep, loose bases are less likely to work. Might want to wait to see if it sets up again in a more-bullish pattern.

Yahoo | June 30, 2020

Illumina unveils its Cambridge accelerator trio, with support from Combined Authority

Alchemab Therapeutics, Neurolytic Healthcare and Tailor Bio will benefit from a package of support.

Cambridge Independent | June 29, 2020

GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

GILD vs. ILMN: Which Stock Is the Better Value Option?

Yahoo | June 29, 2020

Here's Why You Should Hold on to Illumina Stock for Now

Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.

Yahoo | June 29, 2020

Illumina: A Growth Leader In The Genomic Revolution

The genomics revolution will offer extraordinary opportunities for growth in the years ahead, and Illumina (ILMN) is in a position of strength to benefit from those opportunities. The company is at the same time a major driving force and one of the main beneficiaries of the genomics boom. Illumina has...

Andres Cardenal, CFA on Seeking Alpha | June 25, 2020

Read More 'ILMN' Stories Here

ILMN Price Returns

1-mo 3.71%
3-mo 29.38%
6-mo 10.91%
1-year -1.36%
3-year 116.21%
5-year 69.57%
YTD 12.17%
2019 10.61%
2018 37.27%
2017 70.64%
2016 -33.30%
2015 3.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.6601 seconds.